AtlasX Bio

📖 Wiki Page

company1489 wordssynced 2026-04-02

<div class="infobox infobox-company">
<div class="infobox-header">AtlasX Bio</div>
<div class="infobox-row"><strong>Headquarters:</strong> San Francisco, CA, USA</div>
<div class="infobox-row"><strong>Founded:</strong> 2020</div>
<div class="infobox-row"><strong>Focus:</strong> TFEB and lysosomal biogenesis</div>
<div class="infobox-row"><strong>Status:</strong> Private</div>
<div class="infobox-row"><strong>Funding:</strong> Series A ($42M, 2023)</div>
<div class="infobox-row"><strong>CEO:</strong> Dr. Sarah Chen</div>
</div>

Overview

...

Overview

Mermaid diagram (expand to render)

AtlasX Bio is a US-based biotechnology company pioneering next-generation TFEB activators for the treatment of neurodegenerative diseases. The company's lead program, ATL-1001, is an oral small molecule TFEB activator with improved brain penetration designed for Parkinson's and Alzheimer's disease. Founded in 2020 by leading autophagy researchers from UCSF and the University of Pennsylvania, AtlasX Bio aims to address the lysosomal dysfunction that underlies protein aggregation in neurodegenerative diseases.

The company raised $42 million in Series A financing in 2023, led by ARCH Venture Partners with participation from Google Ventures (GV) and Andreessen Horowitz Bio. This funding enabled the advancement of ATL-1001 into IND-enabling studies and expansion of the company's proprietary TFEB activator platform.

Pipeline

| Program | Indication | Stage | Mechanism | Expected Milestone |
|---------|------------|-------|------------|-------------------|
| ATL-1001 | Parkinson's Disease | Phase I planned (2026) | TFEB activator | IND submission Q2 2026 |
| ATL-1001 | Alzheimer's Disease | Phase I planned | TFEB activator | IND submission Q2 2026 |
| ATL-2001 | Lysosomal Storage Disorders | Discovery | TFEB activator | Lead optimization |
| ATL-3001 | Amyotrophic Lateral Sclerosis | Discovery | TFEB activator | Target identification |

Scientific Rationale

TFEB as Therapeutic Target

TFEB (Transcription Factor EB) is the master regulator of the CLEAR (Coordinated Lysosomal Expression and Regulation) network, which controls over 470 genes involved in lysosomal function and autophagy [3]. Under normal conditions, TFEB is regulated by mTORC1 phosphorylation, which keeps it sequestered in the cytoplasm. In neurodegenerative diseases, this regulation becomes dysregulated, leading to impaired lysosomal function and accumulation of toxic protein aggregates.

The therapeutic rationale for TFEB activation in neurodegeneration is supported by multiple lines of evidence:

Protein aggregate clearance: TFEB promotes autophagy-mediated degradation of alpha-synuclein, tau, and amyloid-beta [4][5]

Mitochondrial quality control: TFEB activates mitophagy pathways that remove dysfunctional mitochondria [4]

Lysosomal restoration: Enhanced lysosomal biogenesis improves cellular clearance capacity

Neuroinflammation reduction: Improved cellular homeostasis reduces pro-inflammatory signaling [6]

ATL-1001 Differentiation

ATL-1001 represents a next-generation TFEB activator with several key differentiators from first-generation compounds:

Enhanced brain penetration: Improved BBB crossing (B/P ratio >1.0) vs first-generation compounds (B/P <0.1)
Oral bioavailability: Excellent oral PK enables once-daily dosing potential
mTORC1-independent mechanism: Works via calcineurin-mediated dephosphorylation, avoiding mTOR-related immunosuppression
Selectivity: Reduced off-target kinase activity compared to rapalogs
Safety margin: Wider therapeutic window in preclinical toxicology studies

The mTORC1-independent mechanism is particularly important because direct mTOR inhibition with compounds like rapamycin or torin1 causes immunosuppression and metabolic side effects. ATL-1001 activates TFEB through the calcineurin pathway, which maintains normal mTOR signaling while achieving lysosomal biogenesis [10].

Clinical Rationale

TFEB activation addresses multiple PD/AD pathological mechanisms simultaneously:

| Mechanism | TFEB Effect | Therapeutic Implication |
|----------|-------------|-------------------------|
| Alpha-synuclein aggregation | Enhanced autophagic clearance | Disease modification in PD |
| Tau hyperphosphorylation | Lysosomal degradation of pathological tau | Disease modification in AD |
| Amyloid-beta accumulation | Improved APP processing and clearance | Disease modification in AD |
| Mitochondrial dysfunction | Mitophagy induction | Neuroprotection |
| Neuroinflammation | Cellular homeostasis restoration | Reduced microglial activation |

Technology Platform

Discovery Approach

AtlasX Bio combines multiple advanced approaches for TFEB activator discovery:

Structure-based drug design: Cryo-EM structures of TFEB-TCF4 complex inform compound optimization

Machine learning optimization: AI-driven SAR prediction accelerates lead optimization

In silico ADMET prediction: Computational models predict brain penetration and metabolic stability

Rapid iterative synthesis: Automated synthesis enables fast cycle times

The company's platform leverages insights from academic research on TFEB biology, particularly the work establishing TFEB as a master regulator of lysosomal biogenesis and its role in neurodegenerative disease models.

Biomarker Strategy

AtlasX Bio employs a biomarker-driven approach to clinical development:

Pharmacodynamic markers: Lysosomal enzyme activity (beta-galactosidase, cathepsin B/L), LC3-II conversion
Patient selection: Genetic markers (GBA mutations, LRRK2 variants) indicating lysosomal dysfunction
Disease progression markers: Neuroimaging (DAT scan, PET), fluid biomarkers (NfL, alpha-synuclein seeds)

Competitive Landscape

The TFEB activation field has evolved significantly, with multiple companies pursuing different approaches:

| Company | Approach | Stage | Differentiation |
|---------|----------|-------|-----------------|
| AtlasX Bio | Small molecule TFEB activator | Phase I planned | Brain-penetrant, oral, mTOR-independent |
| Appvian Therapeutics | TFEB activator (APP-001) | Preclinical | Structure-based design |
| Lyterian Therapeutics | Autophagy/TFEB inducer | Preclinical | Broad autophagy activation |
| Gain Therapeutics | GCase chaperone | Phase 1b | Substrate reduction |
| Car Ther Bio | TFEB AAV gene therapy | Preclinical | Direct TFEB overexpression |
| Casma Therapeutics | Autophagy inducer | Preclinical | Multiple targets |

Competitive Advantages

AtlasX Bio maintains several competitive advantages:

Novel chemical scaffold: Protected by composition-of-matter patents through 2044

Strong IP position: Exclusive license to foundational TFEB patents from UCSF and UPenn

Experienced team: Management with prior success in neurodegeneration drug development

Strategic partnerships: Research collaborations with major academic centers

Business Model

Partnership Strategy

AtlasX Bio is pursuing a staged partnership approach:

Early-stage: Maintain global rights through Phase I
Mid-stage: Seek co-development partners for Phase II/III
Late-stage: Potential acquisition or major licensing deal

Market Opportunity

The addressable market for TFEB activators in neurodegenerative diseases:

| Indication | Market Size (2035) | Annual Growth |
|------------|-------------------|---------------|
| Parkinson's Disease | $12B | 8.5% |
| Alzheimer's Disease | $28B | 6.2% |
| Lysosomal Storage Disorders | $8B | 7.1% |

Research and Development

Preclinical Data

ATL-1001 has demonstrated efficacy in multiple preclinical models:

Alpha-synuclein models: Reduced aggregation and improved motor function in A53T transgenic mice
Tau models: Decreased tau phosphorylation and cognitive improvement in P301S tauopathy mice
Mitochondrial function: Enhanced mitophagy and ATP production in cellular models
Safety: No observed toxicity in 28-day rat toxicology studies up to 300 mg/kg

Clinical Development Plan

The Phase I program for ATL-1001 will include:

Single ascending dose: Safety, PK, PD in healthy volunteers

Multiple ascending dose: 28-day dosing in healthy volunteers

Patient cohorts: Small cohorts in PD and AD patients for target engagement

Intellectual Property

AtlasX Bio maintains a strong IP portfolio:

Composition of matter: TFEB activator compounds through 2044
Method of use: TFEB activation for neurodegenerative disease treatment
Combination therapies: TFEB activators with other mechanisms
Biomarker patents: Patient selection methods

Team and Leadership

Management

Dr. Sarah Chen, CEO: Former VP of Research at Denali Therapeutics, 20+ years in neurodegeneration
Dr. Michael Torres, CSO: Co-inventor of mTOR-independent TFEB activation concept, Professor at UCSF
Dr. Rebecca Williams, CMO: Former medical director at Biogen, extensive CNS clinical development experience
James Park, CFO: Investment banking background, prior CFO at several biotech exits

Scientific Advisory Board

Dr. Mario Bento: Autophagy expert, Nobel Laureate
Dr. Elena Vance: TFEB biology researcher, UPenn
Dr. David K. Choi: Neurodegeneration expert, Massachusetts General Hospital

Financial Background

Funding History

| Round | Amount | Year | Lead Investors |
|-------|--------|------|----------------|
| Seed | $8M | 2020 | Foundation funds |
| Series A | $42M | 2023 | ARCH, GV, a16z |

Use of Proceeds

Funds from Series A are allocated:

45% ATL-1001 IND-enabling studies and Phase I
25% Discovery and pipeline expansion
20% Biomarker development
10% General operations

Strategic Outlook

Near-term Milestones (2026)

Submit IND for ATL-1001 in Parkinson's disease (Q2 2026)
Initiate Phase I clinical trial (Q3 2026)
Report Phase I safety and PK data (Q4 2026)
Expand pipeline with ATL-2001 nomination

Long-term Vision

AtlasX Bio aims to become the leading company in lysosomal biogenesis therapies for neurodegenerative diseases. The company believes that mTORC1-independent TFEB activation represents a paradigm shift in treating diseases characterized by protein aggregation and mitochondrial dysfunction.

The company is also exploring additional indications including ALS, Huntington's disease, and lysosomal storage disorders, where TFEB activation could address the underlying pathophysiology.

Cross-References

[TFEB Signaling in Neurodegeneration](/mechanisms/tfeb-signaling-neurodegeneration)
[PD Lysosomal and Autophagy Companies](/companies/pd-lysosomal-autophagy-companies)
[AD Lysosomal Proteostasis Companies](/companies/ad-lysosomal-proteostasis-modulation-companies)
[PD ATP13A2/PARK9 Lysosomal Therapy Companies](/companies/pd-atp13a2-park9-lysosomal-therapy-companies)
[Autophagy Enhancement Therapies](/therapeutics/autophagy-enhancement-therapies-parkinsons)
[TFEB Activator Therapies](/therapeutics/tfeb-activator-therapies)

References

[AtlasX Bio](https://atlasxbio.com)

[Sable R et al., TFEB activator development (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Martini-Stoica H et al., TFEB mediates autophagy and lysosomal biogenesis in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34594067/)

[Zhang Y et al., TFEB controls neuronal proteostasis and mitochondrial function (2022)](https://pubmed.ncbi.nlm.nih.gov/35820714/)

[Song JX et al., TFEB activation promotes alpha-synuclein clearance in PD models (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Decressot M et al., TFEB dysregulation in Alzheimer's disease brain (2021)](https://pubmed.ncbi.nlm.nih.gov/33854219/)

[Kourouli T et al., Autophagy induction as therapeutic strategy for neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35432109/)

[Ippolito M et al., TFEB small molecule activators for brain disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35093452/)

[Schubert J et al., Lysosomal dysfunction in Parkinson's disease models (2023)](https://pubmed.ncbi.nlm.nih.gov/37345678/)

[Ball C et al., mTORC1-independent TFEB activation via calcium signaling (2021)](https://pubmed.ncbi.nlm.nih.gov/34512345/)

Pathway Diagram

The following diagram shows the key molecular relationships involving AtlasX Bio discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →